IL6 and coronary artery disorder: Firstly, according to the subgroup analysis of this study, drugs targeting the central IL-6 inflammatory signaling pathway, such as colchicine, canakinumab, and methotrexate, can reduce cardiovascular events in patients with CAD, while PLA2 inhibitors cannot.